Status:
ACTIVE_NOT_RECRUITING
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Lead Sponsor:
Intergroupe Francophone du Myelome
Collaborating Sponsors:
Janssen-Cilag Ltd.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary o...
Eligibility Criteria
Inclusion
- Adult patient (≥18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose)
Exclusion
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data
- Patients who received teclistamab as part of an interventional clinical trial
- Patients who are initiating teclistamab as part of a current interventional clinical trial
Key Trial Info
Start Date :
September 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06062537
Start Date
September 19 2023
End Date
September 1 2026
Last Update
May 23 2025
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens Picardie
Amiens, France
2
CH d'ANNECY
Annecy, France
3
Centre hospitalier d'Argenteuil
Argenteuil, France
4
Hopital de la cote Basque
Bayonne, France